First U.S. sales of Komzifti (ziftomenib) triggers $135 Million milestone payment to Kura Oncology under collaboration and license agreement with Kyowa Kirin

Kura Oncology, Inc. announced the first U.S. commercial sale of Komzifti (ziftomenib) has been completed. Under Kura’s collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc.

This milestone triggers a $135 million payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. Komzifti was  recently approved by the FDA on November 13, 2025.